'Trade cautiously until unwinding cools off; Biocon among top 3 trading ideas'
For the rest of the week the range looks shifted towards 11,700-11,350 as of now.02-09-2020
02-09-2020
Biocon shares jump 5% on launch of diabetes drug in US
As per a regulatory filing on BSE, Biocon Biologics India, a subsidiary of Biocon, and Mylan N.V., announced the US launch of Semglee.01-09-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Biocon Biologics and Mylan Announce Launch of Semglee(tm) (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes.31-08-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
Intimation pursuant to Regulation 30 of SEBI Listing Regulations, amendment in Memorandum of Association of the Company.21-08-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meeting20-08-2020
India can use pandemic opportunity to become an innovator, says Biocon's Shaw
Kiran Mazumdar Shaw, chairperson and managing director of Biocon, said India must leverage its resources to become a key component of the global innovation value chain .Shaw said that the pandemic also brought the focus on India's roadmap for its presence in the pharmaceutical sector19-08-2020
Biocon chief Kiran Mazumdar-Shaw tests COVID-19 positive; Anand Mahindra, Shashi Tharoor wish speedy recovery
Replying to her tweet, Congress MP Shashi Tharoor said, 'So sorry to hear this. We need you hale and hearty soon! Be well, my friend'18-08-2020
Self-reliance to determine how high flag of freedom flies, says India Inc
Welcoming the National Digital Health Mission, Biocon CMD Kiran Mazumdar Shaw said it gives India's healthcare sector a digital backbone15-08-2020
BIOCON LTD. - 532523 - Disclosure Pursuant To SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 Dated May 20, 2020 ("SEBI Circular') - Impact Of Covid-19 Pandemic.
Dear Sir/Madam, Please find enclosed the disclosure on impact of COVID-19 pandemic on our Company as required under SEBI Circular as Annexure A. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the same on record and acknowledge.14-08-2020
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Investor Meetings14-08-2020